Absstract of: CN113730373A

本发明提供了一种用于递送姜黄素的zein‑AOS复合纳米颗粒及其制备方法。本发明制备的zein‑AOS复合纳米颗粒在适宜的pH及温度条件下，相对稳定，姜黄素的包封率达89.7％，该纳米颗粒在模拟胃液(SGF,pH 2.0)中能够减少姜黄素的释放(<33％)，在模拟肠液(SIF,pH 7.4)中充分释放姜黄素，释放率达83.8％。

Absstract of: CN113730579A

一种由细胞蛋白包裹的黑磷及其制备方法，属于纳米材料表面改性技术，包括（1）黑磷纳米片和黑磷量子点的制备：研磨和超声后，液相剥离以及梯度离心出分散好、粒径分布在50‑300nm的黑磷纳米片以及粒径分布在4‑20 nm黑磷量子点的；（2）细胞蛋白的制备：体外培养的细胞经过裂解液裂解后，离心收集得到细胞蛋白；（3）细胞蛋白包裹黑磷：细胞蛋白与黑磷纳米片或者黑磷量子点混合超声后通过共挤出法制备出保护黑磷氧化、减缓降解速度、粒径分布均匀、生物相容性好且具有靶向细胞的表面包裹有细胞蛋白的黑磷纳米片。本发明为防止黑磷氧化、赋予黑磷目的细胞靶向性以及促进黑磷在植入环境中热疗以及光动力治疗领域方面具有广泛的应用价值。

Absstract of: CN113730562A

本发明专利公开了一种以壳聚糖修饰PLGA的WT1多肽纳米粒疫苗及其制备方法和应用，该纳米粒疫苗粒径为1nm～300nm，PDI分散指数小于0.3；其制备方法如下：将WT1多肽加入到含聚乙烯醇和多磷酸钠的溶液中，然后搅拌下加入丙酮溶解的聚乳酸‑羟基乙酸共聚物溶液，接着搅拌下加入冰醋酸溶解的壳聚糖溶液，充分分散，过滤，离心洗涤获得纳米粒疫苗。该纳米粒疫苗，且质量稳定，分散性良好，可诱导机体产生高效的免疫应答对，对白血病及相关肿瘤疾病的预防和治疗具有重要意义。

Absstract of: CN113736024A

本发明公开了一种蔗渣木聚糖琥珀酸酯‑g‑HEMA/EGDMA‑Cur的制备方法。以蔗渣木聚糖为原料，甲基丙烯酸羟乙酯、乙二醇二甲基丙烯酸酯为接枝单体，过硫酸铵为引发剂，在水溶剂中通过自由基反应合成蔗渣木聚糖三元接枝共聚物BX‑g‑HEMA/EGDMA；以4‑二甲氨基吡啶为催化剂，在氯化1‑烯丙基‑3‑甲基咪唑溶液中，通过酯化反应合成蔗渣木聚糖琥珀酸酯‑g‑HEMA/EGDMA；采用乳化分散‑TPP交联法制备蔗渣木聚糖琥珀酸酯‑g‑HEMA/EGDMA‑Cur纳米粒。本发明所得产物提高了蔗渣木聚糖分子链上活性羟基的利用率，优化了其功能特性和生物活性，拓宽了其在高分子材料及药物载体领域的应用范围。

Absstract of: CN113730597A

本发明提供一种基于淀粉‑姜黄素偶联物的微纳米载体及其应用。所述淀粉‑姜黄素偶联物的重复结构单元具有下式所示的结构，其中R1，R2和R3基团的数目均为在0~5之间的整数，R4和R5基团的数目均为在1~6之间的整数，R1~R5基团的数目之和等于6；R1~R5基团在环结构上的分布为随机分布；X为介于1~8之间的整数；n为聚合物结构中该重复单元的个数，为10~100000之间的整数。该淀粉‑姜黄素偶联物用于制备载药微纳米载体，可包载具有不同物理化学性质的药物，同时姜黄素本身具有抗癌、抗炎、抗菌等各种药理活性。故基于淀粉‑姜黄素偶联物的微纳米载体可作为新型药物递送系统用于各种疾病的治疗。

Absstract of: CN113735993A

本发明提供了一种透明质酸载体的制备方法，包括以下步骤：S1，将大分子透明质酸钠用透明质酸酶酶解成透明质酸钠寡糖分子；S2，将透明质酸钠寡糖分子在偶联剂存在的条件下与胱胺二盐酸盐缩合反应，制成透明质酸单二硫键产物；S3，取一份透明质酸单二硫键产物在酸性催化的条件下缓慢添加到一份透明质酸单二硫键产物中，脱水缩合形成所述透明质酸载体。所述透明质酸载体的灵活性高，应用范围广阔，同时其运载效率高。

Absstract of: CN113730612A

本发明涉及生物医药技术领域，提供了一种改性的磁性纳米颗粒及其制备方法和应用。所述的改性磁性纳米颗粒的核心为磁性金属氧化物，所述磁性金属氧化物的表面至少部分包裹有二氧化硅涂层，二氧化硅涂层表面修饰氟硅烷。本发明改性的磁性纳米颗粒具有很高的磁性和氟相容性，具有广阔的应用前景，特别适合用于磁性超声造影剂中，使所得的磁性超声造影剂能够更好地满足外部刺激靶向递送的要求，从而实现药物的局部高浓度靶向递送。

Absstract of: CN113730607A

本发明属于生物医药技术领域，具体涉及携载氧全氟丙烷及吲哚菁绿的纳米载药系统的制备方法，包括如下步骤：S1：制备PLGA二氯甲烷溶液，MTX溶液，ICG超纯水溶液，聚乙烯醇超纯水溶液；S2：声振得到一级乳化液以及二级乳化液；S3：将S2得到的二级乳化液搅拌后高速离心，沉淀物用超纯水反复洗涤及高速离心两次，洗涤至上清液澄清后重悬于超纯水中，放4℃保存备用；本方法制备的纳米粒负载活性成分明确、药剂学特性稳定、具有良好的类风湿关节炎受累关节靶向分布作用，对滑膜异常增生和局部缺氧有积极作用。

Absstract of: CN113735949A

本发明涉及无乳链球菌表面免疫原性重组蛋白及其制备方法与应用，所述重组蛋白的氨基酸序列如SEQ ID NO:2所示，所述重组蛋白的编码基因的序列如SEQ ID NO:1所示；所述重组蛋白的制备方法即将所述的重组蛋白的编码基因构建到表达载体上，获得重组表达载体；将重组表达载体转化宿主细胞，培养转化的宿主细胞，使转化的宿主细胞表达产生所述无乳链球菌表面免疫原性重组蛋白，之后回收并纯化所表达的无乳链球菌表面免疫原性重组蛋白；所述重组蛋白在制备罗非鱼抗无乳链球菌感染的疫苗中的应用。一种罗非鱼口服纳米疫苗是以所述的无乳链球菌表面免疫原性重组蛋白作为抗原；本发明的纳米疫苗对罗非鱼具有良好的免疫保护效果。

Absstract of: CN113730576A

本发明属于脱毛技术领域，具体公开了一种激光脱毛的纳米光热材料及其制备方法，纳米光热材料的组分包括光热染料和载体，载体包裹光热染料形成纳米颗粒；纳米颗粒的粒径为50‑300nm。纳米光热材料的制备方法，包括以下步骤：将光热染料和载体混合后，制得纳米光热材料。本发明基于纳米光热材料促进毛发脱落，通过局部涂抹载有具光热效应的纳米光热材料，由于纳米光热材料的粒径小，其在皮肤部位涂抹后容易富集在毛囊部位，纳米光热材料通过吸收激光的光能产生光热效果，将光能迅速转换成热能，并借助热能使毛囊坏死，从而达到毛发不再生长的目的。

Absstract of: US2021369844A1

The present invention provides an apparatus for targeting and disrupting, deactivating or destroying microorganisms (e.g. viruses, bacteria, fungus or diseased cells). The apparatus includes Field-Electric Nano-Particles coated, conjugated or functionalized with one or more guiding agents such as antibodies or proteins that target a type of bacteria, fungus, virus or diseased cells; a delivery module to deliver such nanoparticles into a subject's body, and an external energy field generation module. The nanoparticles, when subject to the applied external energy field, generate an electric field or pulses of electric field localized to the targeted bacteria, fungus or virus to disrupt, deactivate or destroy the targeted bacteria, fungus, viruses, or diseased cells.

Absstract of: WO2020026102A1

Disclosed are methods of treating cancer comprising administering to a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition comprising a plurality of AZD2811 nanoparticles and an effective amount of 5-azacitidine.

Absstract of: WO2020026100A1

Disclosed are methods of treating cancer comprising administering to a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition comprising a plurality of AZD2811 nanoparticles and venetoclax.

Absstract of: WO2019231051A1

The present invention relates to a nanoparticle composite, which is endocytosed into cells and used to treat a disease, and to a manufacturing method therefor. More specifically, the present invention relates to a nanoparticle composite and a manufacturing method therefor, wherein the nanoparticle composite shows improved endocytosis efficiency by modifying the nanoparticle surface with a lipid-based material having high stability and excellent biocompatibility; the nanoparticle composite can attain direct passage through the cellular membrane as well as endocytosis, and can be effectively endocytosed into spheroid-shaped tumor cells, by having a tube-shaped lipid structure combined with a portion of the nanoparticle surface; and the nanoparticle composite can be easily mass-produced by using a top-down manner, in which, the lipid structure is not attached directly to the nanoparticle, but the binding of the nanoparticle and the lipid-based lipidome (bubble, liposome, etc.) is induced, and then the physical force is applied thereto to disrupt the lipidome, thereby forming the lipid structure on the nanoparticle surface.

Absstract of: WO2020030654A1

The present invention relates to polypeptides self-assembling into nanoparticles. In particular, the invention relates to a polypeptide comprising an amino acid sequence I (SEQ ID NO: 1), a nucleic acid sequence encoding said polypeptide, a nanoparticle comprising at least one polypeptide of the invention, a complex comprising said nanoparticle and one or more cargo molecules, and a method for transfecting a cell with said complex.

Absstract of: AU2020200252A1

Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells. See Fig. 2.

Absstract of: AU2020200252A1

Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells. See Fig. 2.

Absstract of: AU2020200252A1

Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells. See Fig. 2.

Absstract of: WO2021241966A1

The present invention relates to a Prussian blue/pluronic nanoparticle complex for removal of reactive oxygen, and a use thereof. The Prussian blue/pluronic nanoparticle complex according to the present invention exhibits excellent reactive oxygen removal activity and wound healing ability and is stable as well as being superbly biocompatible and, as such, can be effectively used in a pharmaceutical composition, a quasi-drug composition, a cosmetic composition, and a food composition, for use in removing reactive oxygen, and for developing a method for preventing, alleviating, or treating diseases or symptoms caused by excessive generation of reactive oxygen.

Absstract of: WO2021241490A1

The present invention addresses the problem of providing: nanoparticles of cerium oxide having high oxidizing performance, antiviral performance, and antibacterial performance; and a dispersion including nanoparticles of cerium oxide. The present invention is nanoparticles of cerium oxide produced by adding an oxidizing agent to a solution that contains a boron compound represented by general formula (I) and cerium(III) ions.　Formula (I): BRn(OR')3-n In formula (I), n is an integer of 0-2, R represents either a C1-4 alkyl group, a phenyl group, or a tolyl group, and R' represents either a C1-4 alkyl group, a phenyl group, or a tolyl group. When multiple R or R' are present, each may be the same or different.

Absstract of: WO2021242917A1

A method that includes detecting the presence of a pancreatic intraepithelial neoplasia lesion in a subject in vivo comprising administering to the subject a construct, or a pharmaceutically acceptable salt thereof, wherein the construct comprises: (a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized; (b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and (c) a detectable moiety complexed with, or conjugated to, the poly(L-lysine) of the polymer moiety, wherein the construct is neutralized.

Absstract of: WO2021242794A2

Described herein are functionalizing nanocomplexes comprising one or more polyphenol molecules; and one or more biomolecules. Further described herein are functionalized cells comprising one or more of the nancomplexes. In some embodiments, the biomolecules can be therapeutic agents and the functionalized cells can be administered to patients to provide improved delivery (e.g., dosing and specificity) of the therapeutic agent.

Absstract of: WO2021240099A1

The present invention concerns the use of a linear or optionally branched terpene having at most one C=C unsaturation for producing conjugates having self-assembly properties, and a self-assembly agent of formula (I): X(-Spacer-Y-Terpene)p (I) in which "Terpene" is linear or optionally branched and has at most one C=C unsaturation; "Y" is a bond or a molecular fragment having a biodegradable bond; "Spacer" is a bond or a fragment comprising at least one carbon atom; "X" is a molecular fragment comprising at least one biodegradable bond; "p" is between 0.1 and 4; and the group "Spacer-Y-" may optionally be a bond; and also the conjugate obtained by combining the self-assembly agent of formula (I) with an active molecule AM.

Absstract of: WO2021242545A1

Disclosed are agents that include a flavanol (e.g., epigallocatechm-3-gailate) or a flavanol analog, a linker coupled to the flavanol or the flavanol analog, and a earner (e.g., iron oxide nanoparticle) coupled to the linker. The disclosed agents can be used in methods tor destabilizing a tau amyloid fibril, and for treating a tauopathy (e.g., Alzheimer's disease, progressive supranuclear palsy) in a subject.

Absstract of: WO2021239787A1

The present invention refers to a novel methacrylic copolymer comprising units derived from at least one alkyl methacrylate and methacrylamide, wherein the units derived from methacrylamide are present in at least 34 wt.-%, based on the total weight of the copolymer. Furthermore, the present invention refers to a method of preparing these novel methacrylic copolymers. Moreover, the present invention refers to pharmaceutical compositions, nutraceutical compositions, coated pharmaceutical or nutraceutical dosage forms as well as nano- or microparticles comprising the methacrylic copolymer of the present invention. Finally, the present invention refers to the use of the methacrylic copolymer of the present invention as coating, as carrier, and as matrix for an amorphous solid dispersion.